Compounding pharmacies and the telehealth platforms that sell their preparations, particularly semaglutide and tirzepatide products, are now drawing attention from two federal regulators at once. The Food and Drug Administration (FDA) has sent warning letters to telehealth and compounding companies over marketing language calling a compounded drug a "generic" version of, or claiming it has the "same" safety and effectiveness as, an approved product, while the Federal Trade Commission (FTC) separately enforces its own prohibition on false and unsubstantiated advertising under Section 5 of the FTC Act against the same advertisements. A pharmacy that satisfies its FDA compounding requirements can still create FTC exposure from the same web page, the same patient testimonial, or the same social media post.
FDA Treats Marketing Claims as a Misbranding Issue
A drug compounded under Section 503A/503B of the Federal Food, Drug, and Cosmetic Act is exempt from certain requirements that apply to a conventionally manufactured drug, including premarket approval, but that exemption does not extend to advertising. FDA's warning letters to compounders and telehealth marketers have targeted language stating or implying that a compounded drug is a generic version of, or has the same safety and effectiveness as, an FDA-approved product. Compounded drugs are not FDA-approved, and the agency has not reviewed their safety, effectiveness, or quality before they reach a patient. Labeling or promotional material that is false or misleading in any particular can render the product misbranded, exposing a 503B outsourcing facility or a 503A pharmacy to a warning letter, an injunction, or a product seizure. The enforcement risk has followed tirzepatide compounders in particular as products have moved on and off FDA's drug shortage list.
FTC Applies Its Own Standard to the Same Ads
The FTC does not need FDA to act first. Section 5 of the FTC Act independently prohibits unfair or deceptive advertising, and FTC guidance requires competent and reliable scientific evidence, typically well-controlled human clinical studies, before a pharmacy or telehealth marketer makes an efficacy or safety claim. Consumer advocacy groups have petitioned the FTC directly over compounded GLP-1 advertising, pointing to ads that imply comparable safety and efficacy to an approved drug without the clinical evidence to support the comparison. A claim that satisfies FDA's compounding-specific rules is not automatically safe from an FTC challenge, because the two agencies apply separate standards to the same advertisement. An ad that overstates equivalence, omits a material limitation, or relies on a patient testimonial in place of clinical evidence can violate the FTC standard even where no FDA labeling violation has been identified.
Marketing language that clears FDA's compounding-specific rules can still violate the FTC's separate deceptive-advertising standard, and a single advertisement can generate exposure with both agencies at once.
Where Promotional Language Crosses the Line
Not every promotional statement carries the same risk. A pharmacy may truthfully describe its own compliance with cGMP requirements, its adherence to USP 797/800 sterile and hazardous compounding standards, the topic of its own USP 797 and 800 inspection readiness, or its practice of assigning an accurate beyond-use date to every preparation. Those are verifiable statements about the pharmacy's own operations. The exposure begins when the marketing shifts from describing the pharmacy's process to describing the drug's outcome, claiming it works as well as, is identical to, or is a safer alternative to an FDA-approved product, without the substantiation the FTC requires or the disclosures the FDA expects. A pharmacy's public marketing claims and the statements it makes to an inspector during a state board compounding inspection should be reviewed together, since an inconsistency between the two can compound the exposure on both fronts.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies and telehealth marketing partners retain experienced healthcare defense counsel before finalizing advertising copy, and immediately upon receiving an FDA warning letter or an FTC inquiry. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to a government request, avoid inadvertent admissions in a written reply, and preserve relevant defenses. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance has represented 2,500+ clients over 25+ years, including compounding pharmacies and telehealth marketing partners navigating FDA and FTC scrutiny of their advertising. Our compounding pharmacy attorneys review promotional claims before they run, respond to warning letters and civil investigative demands, and represent pharmacies once an inquiry becomes an enforcement action. Contact Health Law Alliance for a free, confidential consultation.
